Cero Therapeutics Secures $2.09M 10% Convertible Note With SRX Global, Maturing May 2027TradingView·Jul 17 at 03:43 PMCERO-11.50%SRXH0.00%
Delisting of Securities from The Nasdaq Stock Market | NDAQ Stock NewsStockTitan·Jul 10 at 03:00 AMBTM0.00%BOWN0.00%
Cero Therapeutics amends SRX Health promissory note, lifts borrowing capacity to $1.41 millionPUBT·Jun 26 at 03:06 PMCERO-11.50%SRXH0.00%
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentUnusual Whales·Jun 15 at 07:16 AMCERO-11.50%
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | CERO Stock NewsStockTitan·May 10 at 11:15 PMCERO-11.50%BBH-0.23%
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock NewsStockTitan·Apr 13 at 11:15 PMCERO-11.50%IBB-0.44%
Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | B Stock NewsStockTitan·Mar 30 at 06:15 PMCERO-11.50%BBH-0.23%
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial | CERO Stock NewsStockTitan·Mar 29 at 11:15 PMIBB-0.44%LABU-3.22%
Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | B Stock NewsStockTitan·Mar 16 at 10:40 PMBBH-0.23%PBE-0.38%
CERo Therapeutics Provides Shareholder Update | CERO Stock NewsStockTitan·Mar 10 at 11:15 PMBBH-0.23%LABD+3.66%
